Hot Stocks | Here's why LIC Housing Finance and Glenmark Pharma are top buys
It is better not to trade aggressively in the index and carrying of overnight positions is strictly avoided, said Sameet Chavan.10-05-2021
10-05-2021
Glenmark Pharma launches nasal spray Ryaltris in India
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.03-05-2021
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches Ryaltris(r)-AZ at an affordable price in India03-05-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Acquisition
This is to inform you that Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP). The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure - A.30-04-2021
Glenmark Pharmaceuticals Ltd - 532296 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGLENMARK PHARMACEUTICALS LTD. 2CINL24299MH1977PLC019982 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harish Kuber Designation: Company Secretary & Compliance Officer EmailId: complianceofficer@glenmarkpharma.com Name of the Chief Financial Officer: VS Mani Designation: Executive Director & Global CFO EmailId: complianceofficer@glenmarkpharma.com Date: 26/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.26-04-2021
Glenmark Pharma to launch its nasal spray Ryaltris in European Union
Glenmark said Ryaltris is now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age.26-04-2021
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark's Ryaltris (r) nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.26-04-2021
Glenmark Arm Files Papers For Rs 1,160 Crore Glenmark Life Sciences' IPO
The IPO comprises a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73.05 lakh equity shares by Glenmark Pharmaceuticals.19-04-2021
Glenmark Pharmaceuticals Ltd - 532296 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer19-04-2021
Glenmark Pharmaceuticals Ltd - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2021
This is to certify that all activities in relation to both physical and electronic share transfer facilities are maintained by Registrar to an issue and Share Transfer Agent 'M/s. KFin Technologies Private Limited' registered with Securities Exchange Board of India under Registration Number INR000000221. Please take the same on records.19-04-2021